Twin Tree Management’s TG Therapeutics TGTX Stock Holding History

Twin Tree Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.9M	Buy	+57,300	New	+$1.71M	0.04%	507

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Twin Tree Management's TGTX Position: Q3 2025 in Review

Twin Tree Management sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 27,655 shares — an estimated $995K sold.

Twin Tree Management first reported a position in TGTX in Q2 2023 and held it in 5 quarters. The position peaked at $995K in Q2 2025. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

Twin Tree Management reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
Twin Tree Management sold 27,655 TG Therapeutics shares in Q3 2025, an estimated $995K.
Twin Tree Management first reported a position in TG Therapeutics in Q2 2023 and held it in 5 quarters.
Twin Tree Management's TG Therapeutics position peaked at $995K in Q2 2025.
354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Twin Tree Management's 13F filing for Q3 2025, filed 13 Nov 2025.